A Phase 3 interventional study of Nivolumab + Relatlimab and rHuPH20 in Melanoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 149 sites in 19 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 62 under way, 9 of them phase 3. Nivolumab · Melanoma.
Among the 142 studies testing nivolumab in Melanoma, this one is the 9th largest by enrollment, is one of 12 that started in 2023, is one of 19 in phase 3, reaches primary completion later than 18 of the 61 other live ones, and was the 108th registered.
3,374 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Melanoma and Skin Cancer Trials Limited · Sites in Australia
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 20 · Phase 4 4
First in 2006; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 579 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 50 across the 142 interventional studies. Of the 63 that completed or were terminated, 35 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 142 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
111 studies in Melanoma by Bristol-Myers Squibb: 3 open now, 9 under way, 3 of them phase 3. Of 90 finished, 41 (46%) have results posted.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 15th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2023, is one of 21 in phase 3, and was the 105th registered.
Bristol-Myers Squibb’s Melanoma studies by the year they started, since 2002.
13 of the studies testing nivolumab in Melanoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
| NCT07155317Emory UniversityTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | 2026-12-31 |
| NCT03685890Vastra Gotaland RegionEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | 2026-12-31 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 142 studies testing nivolumab in Melanoma, from their registry updates:
Among Bristol-Myers Squibb’s 111 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nivolumab + Relatlimab · Drug: rHuPH20
Drug: Nivolumab + Relatlimab
Drug pages: Nivolumab · Relatlimab
Specified dose on specified days
Also known as: BMS-986213, Opdualag
Specified dose on specified days
Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale
Blood samples were collected to assess serum concentration.
Time frame: Pre-dose (Day 1 to Day 28)
Adjusted Time-Averaged Relatlimab Serum Concentration Over the First 28 Days (Cavgd28-Rela) on Natural Logarithmic Scale
Blood samples were collected to assess serum concentration.
Time frame: Pre-dose (Day 1 to Day 28)
Adjusted Trough Nivolumab Serum Concentration at Steady-State (Cminss-Nivo) on Natural Logarithmic Scale
Blood samples were collected to assess serum concentration.
Time frame: Pre-dose (Day 1 to Day 28)
Adjusted Trough Relatlimab Serum Concentration at Steady-State (Cminss-Rela) on Natural Logarithmic Scale
Blood samples were collected to assess serum concentration.
Time frame: Pre-dose (Day 1 to Day 28)
Objective Response Rate (ORR) by BICR
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Disease Control Rate (ORR) Per BICR
Disease control rate (DCR) is defined as the percentage of participants who achieve a BOR of confirmed Complete Response (CR), confirmed Partial Response (PR), or stable disease (SD), based on BICR assessments (using RECIST 1.1) divided by the number of all randomized participants. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Time to Response (TTR) Per BICR
Time to response (TTR) assessed by BICR is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Duration of Response (DoR) Per BICR
Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR is complete disappearance of all target lesions except nodal disease; all target nodes must decrease to normal size (short axis \< 10 mm). PR is ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. Disease progression is defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Progression Free Survival Per BICR
Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Objective Response Rate (ORR) Per Investigator
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on Investigator assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Disease Control Rate (ORR) Per Investigator
Disease control rate (DCR) is defined as the percentage of participants who achieve a BOR of confirmed Complete Response (CR), confirmed Partial Response (PR), or stable disease (SD), based on Investigator assessments (using RECIST 1.1) divided by the number of all randomized participants. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Time to Response (TTR) Per Investigator
Time to response (TTR) assessed by Investigator is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Duration of Response (DoR) Per Investigator
Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR is complete disappearance of all target lesions except nodal disease; all target nodes must decrease to normal size (short axis \< 10 mm). PR is ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. Disease progression is defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Progression Free Survival Per Investigator
Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Overall Survival (OS)
Overall survival is defined as the time from the first dosing date (or from randomization/on treatment) to the date of death from any cause. Median computed using Kaplan-Meier method.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Trough Serum Concentration of Nivolumab and Relatlimab (Cmind28) at Day 28
Blood samples were collected to assess serum concentration.
Time frame: Pre-dose at Day 28
Peak Serum Concentration (Cmax1) After the First Dose of Nivolumab and Relatlimab
Blood samples were collected to assess serum concentration.
Time frame: Post-dose Day 1
Maximum Observed Concentration at Steady State (Cmaxss) Nivolumab and Relatlimab
Blood samples were collected to assess serum concentration.
Time frame: Post-dose Day 1
Average Observed Concentration at Steady State (Cavgss) of Nivolumab and Relatlimab
Blood samples were collected to assess serum concentration.
Time frame: Post-dose Day 1
Number of Participants With Adverse Events, SAEs, AEs Leading to Discontinuation and Deaths
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence at any dose that: results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions, results in a congenital abnormality or birth defect, or is an important medical event that may not result in death, be life-threatening, or require hospitalization, but may require medical or surgical intervention to prevent any of the outcomes listed above.
Time frame: First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 26 months)
Number of Participants With Immune-mediate Adverse Events (IMAEs)
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.
Time frame: First dose (Day 1) and 135 days after last dose of study therapy (up to approximately 29 months)
Number of Participants With Other Event of Special Interest (OESI)
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.
Time frame: First dose (Day 1) and 100 days after last dose of study therapy (up to approximately 28 months)
Number of Participants With On-Treatment Worst CTCAE Grade 3-4 Laboratory Parameters
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.
Time frame: First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 26 months)
Change From Baseline Functional Assessment of Cancer Therapy -Melanoma (FACT-M) Total Score
The FACT-M questionnaire was used to assess the effects of disease symptoms on functioning and well-being. As a generic cancer-related core, the FACT-M includes the 27-item FACT General (FACT-G) to assess physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). In addition, the FACT-M includes a 16-item disease-specific Melanoma Subscale (MS). Each FACT-M item is rated on a 5-point scale ranging from 0 (not at all) to 4 (very much). Scores for the PWB, FWB, SWB, and EWB subscales can be combined to produce a FACT-G total score, which provides an overall indicant of generic quality of life, while the FACT-G and MS scores can be combined to produce a total score for the FACT-M, which provides a composite measure of general and targeted quality of life. Overall scale ranges from 0 to 172, higher values indicate better functioning as well as lower symptom burden.
Time frame: Baseline (Day 1) and Week 85
| Milestone | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Started | 286 | 292 |
| Completed | 283 | 291 |
| Not completed | 3 | 1 |
| Withdrew: Full withdrawal of consent by subject from study | 1 | 0 |
| Withdrew: Subject no longer meets study criteria | 2 | 1 |
| Milestone | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Started | 283 | 291 |
| Completed | 0 | 0 |
| Not completed | 283 | 291 |
| Withdrew: Other reasons | 1 | 0 |
| Withdrew: Partial withdrawal of consent by subject | 0 | 1 |
| Withdrew: Withdrawal of consent by subject from treatment period | 3 | 4 |
| Withdrew: Full withdrawal of consent by subject from study | 2 | 4 |
| Withdrew: Symptomatic deterioration | 8 | 10 |
| Withdrew: Subject request to discontinue study treatment | 0 | 1 |
| Withdrew: Progressive disease | 108 | 93 |
| Withdrew: Adverse event | 49 | 68 |
| Withdrew: Ongoing treatment | 112 | 110 |
Blood samples were collected to assess serum concentration.
| ug/mL | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale | 4.141 ± 0.0167 | 3.901 ± 0.0164 |
Blood samples were collected to assess serum concentration.
| ug/mL | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Adjusted Time-Averaged Relatlimab Serum Concentration Over the First 28 Days (Cavgd28-Rela) on Natural Logarithmic Scale | 3.120 ± 0.0186 | 2.721 ± 0.0183 |
Blood samples were collected to assess serum concentration.
| ug/mL | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Adjusted Trough Nivolumab Serum Concentration at Steady-State (Cminss-Nivo) on Natural Logarithmic Scale | 4.759 ± 0.0335 | 4.169 ± 0.0330 |
Blood samples were collected to assess serum concentration.
| ug/mL | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Adjusted Trough Relatlimab Serum Concentration at Steady-State (Cminss-Rela) on Natural Logarithmic Scale | 3.629 ± 0.0525 | 2.631 ± 0.0517 |
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Objective Response Rate (ORR) by BICR | 43.0 (37.2 to 49.0) | 50.7 (44.8 to 56.6) |
Disease control rate (DCR) is defined as the percentage of participants who achieve a BOR of confirmed Complete Response (CR), confirmed Partial Response (PR), or stable disease (SD), based on BICR assessments (using RECIST 1.1) divided by the number of all randomized participants. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
| percentage of participants | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Disease Control Rate (ORR) Per BICR | 62.2 (56.3 to 67.9) | 72.3 (66.7 to 77.3) |
Time to response (TTR) assessed by BICR is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Time to Response (TTR) Per BICR | 2.79 (1.6 to 9.2) | 2.79 (1.4 to 17.7) |
Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR is complete disappearance of all target lesions except nodal disease; all target nodes must decrease to normal size (short axis \< 10 mm). PR is ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. Disease progression is defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.
| months | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Duration of Response (DoR) Per BICR | NA (1.5 to 20.4) | NA (1.6 to 20.3) |
Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Progression Free Survival Per BICR | 12.65 (8.08 to NA) | 14.98 (12.12 to NA) |
Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on Investigator assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Objective Response Rate (ORR) Per Investigator | 47.9 (42.0 to 53.9) | 52.4 (46.5 to 58.2) |
Disease control rate (DCR) is defined as the percentage of participants who achieve a BOR of confirmed Complete Response (CR), confirmed Partial Response (PR), or stable disease (SD), based on Investigator assessments (using RECIST 1.1) divided by the number of all randomized participants. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
| percentage of participants | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Disease Control Rate (ORR) Per Investigator | 62.2 (56.3 to 67.9) | 72.3 (66.7 to 77.3) |
Time to response (TTR) assessed by Investigator is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Time to Response (TTR) Per Investigator | 2.83 (1.4 to 12.9) | 2.79 (1.4 to 12.0) |
Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR is complete disappearance of all target lesions except nodal disease; all target nodes must decrease to normal size (short axis \< 10 mm). PR is ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. Disease progression is defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.
| months | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Duration of Response (DoR) Per Investigator | NA (1.5 to 20.4) | NA (1.6 to 20.3) |
Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Progression Free Survival Per Investigator | 10.28 (6.57 to 14.98) | 14.82 (10.15 to NA) |
Overall survival is defined as the time from the first dosing date (or from randomization/on treatment) to the date of death from any cause. Median computed using Kaplan-Meier method.
| months | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Overall Survival (OS) | NA (21.09 to NA) | NA (NA to NA) |
Blood samples were collected to assess serum concentration.
| ug/mL | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Relatlimab | 13.79 ± 70 | 5.10 ± 139 |
| Nivolumab | 44.75 ± 43 | 27.33 ± 48 |
Blood samples were collected to assess serum concentration.
| ug/mL | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Relatlimab | 32.62 ± 36 | 46.70 ± 20 |
| Nivolumab | 88.51 ± 35 | 137.05 ± 24 |
Blood samples were collected to assess serum concentration.
| ug/mL | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Relatlimab | 71.58 ± 44 | 65.42 ± 29 |
| Nivolumab | 203.52 ± 41 | 209.91 ± 27 |
Blood samples were collected to assess serum concentration.
| ug/mL | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Relatlimab | 57.29 ± 49 | 30.29 ± 53 |
| Nivolumab | 164.02 ± 44 | 106.33 ± 39 |
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence at any dose that: results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions, results in a congenital abnormality or birth defect, or is an important medical event that may not result in death, be life-threatening, or require hospitalization, but may require medical or surgical intervention to prevent any of the outcomes listed above.
| Participants | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Death | 11 | 10 |
| Adverse Events | 275 | 285 |
| Serious Adverse Events | 109 | 112 |
| AEs leading to Discontinuation | 39 | 47 |
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.
| Participants | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Pneumonitis | 2 | 6 |
| Diarrhea/Colitis | 17 | 12 |
| Hepatitis | 16 | 11 |
| Nephritis/Renal Dysfunction | 4 | 1 |
| Rash | 25 | 21 |
| Hypersensitivity | 1 | 7 |
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.
| Participants | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Myasthenic syndrome | 0 | 2 |
| Demyelination event | 0 | 0 |
| Guillain-Barre syndrome | 0 | 0 |
| Pancreatitis event | 3 | 5 |
| Uveitis event | 3 | 6 |
| Encephalitis event | 3 | 4 |
| Myocarditis event | 6 | 11 |
| Myositis/rhabdomyolysis event | 5 | 2 |
| Graft Versus Host Disease | 0 | 0 |
| Autoimmune cytopenia | 1 | 0 |
| Autoimmune eye disorder | 0 | 0 |
| Immune mediated arthritis | 0 | 1 |
| Other meningitis event | 0 | 2 |
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.
| Participants | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| HEMOGLOBIN | 12 | 10 |
| PLATELET COUNT | 2 | 1 |
| LEUKOCYTES, LOCAL LAB | 1 | 1 |
| LYMPHOCYTES (ABSOLUTE), LOCAL LAB | 5 | 7 |
| NEUTROPHILS (ABSOLUTE), LOCAL LAB | 3 | 2 |
| ALKALINE PHOSPHATASE, LOCAL LAB | 0 | 2 |
| ASPARTATE AMINOTRANSFERASE, LOCAL LAB | 3 | 4 |
| ALANINE AMINOTRANSFERASE, LOCAL LAB | 3 | 5 |
| BILIRUBIN, TOTAL, LOCAL LAB | 4 | 3 |
| CREATININE, LOCAL LAB | 1 | 4 |
| HYPERNATREMIA | 0 | 0 |
| HYPONATREMIA | 5 | 4 |
| HYPERKALEMIA | 1 | 2 |
| HYPOKALEMIA | 1 | 4 |
| HYPERCALCEMIA | 1 | 1 |
| HYPOCALCEMIA | 1 | 2 |
| HYPOGLYCEMIA | 1 | 0 |
The FACT-M questionnaire was used to assess the effects of disease symptoms on functioning and well-being. As a generic cancer-related core, the FACT-M includes the 27-item FACT General (FACT-G) to assess physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). In addition, the FACT-M includes a 16-item disease-specific Melanoma Subscale (MS). Each FACT-M item is rated on a 5-point scale ranging from 0 (not at all) to 4 (very much). Scores for the PWB, FWB, SWB, and EWB subscales can be combined to produce a FACT-G total score, which provides an overall indicant of generic quality of life, while the FACT-G and MS scores can be combined to produce a total score for the FACT-M, which provides a composite measure of general and targeted quality of life. Overall scale ranges from 0 to 172, higher values indicate better functioning as well as lower symptom burden.
| Score on a scale | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Change From Baseline Functional Assessment of Cancer Therapy -Melanoma (FACT-M) Total Score | 9.76 ± 17.87 | 1.75 ± 15.33 |
Collected over All cause mortality were collected from Day 1 and up to approximately 29 months. SAEs and Non SAEs were collected from first dose (Day 1) and 135 days after last dose of study therapy (up to approximately 29 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivo + Rela FDC SC | 80/286 (28%) | 143/283 (50.5%) | 242/283 (85.5%) |
| Nivo + Rela FDC IV | 63/292 (21.6%) | 140/291 (48.1%) | 261/291 (89.7%) |
| Event | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 24/283 | 23/291 |
| ColitisGastrointestinal disorders | 10/283 | 1/291 |
| Adrenal insufficiencyEndocrine disorders | 9/283 | 5/291 |
| General physical health deteriorationGeneral disorders and administration site conditions | 3/283 | 7/291 |
| MyocarditisCardiac disorders | 5/283 | 6/291 |
| Atrial fibrillationCardiac disorders | 5/283 | 1/291 |
| PneumoniaInfections and infestations | 5/283 | 4/291 |
| Acute kidney injuryRenal and urinary disorders | 2/283 | 5/291 |
| Septic shockInfections and infestations | 4/283 | 1/291 |
| Troponin increasedInvestigations | 4/283 | 2/291 |
| Event | Nivo + Rela FDC SC | Nivo + Rela FDC IV |
|---|---|---|
| FatigueGeneral disorders and administration site conditions | 50/283 | 76/291 |
| PruritusSkin and subcutaneous tissue disorders | 59/283 | 65/291 |
| HypothyroidismEndocrine disorders | 59/283 | 62/291 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 49/283 | 55/291 |
| DiarrhoeaGastrointestinal disorders | 53/283 | 47/291 |
| RashSkin and subcutaneous tissue disorders | 53/283 | 47/291 |
| AstheniaGeneral disorders and administration site conditions | 45/283 | 50/291 |
| NauseaGastrointestinal disorders | 46/283 | 46/291 |
| AnaemiaBlood and lymphatic system disorders | 43/283 | 41/291 |
| HeadacheNervous system disorders | 25/283 | 39/291 |
| Age, Continuous(years) | Nivo + Rela FDC SC | Nivo + Rela FDC IV | Total |
|---|---|---|---|
| Mean | 64.3 ± 13.60 | 63.1 ± 13.58 | 63.7 ± 13.59 |
| Age, Customized(Participants) | Nivo + Rela FDC SC | Nivo + Rela FDC IV | Total |
|---|---|---|---|
| 18-64 years | 130 | 147 | 277 |
| 65-84 years | 150 | 138 | 288 |
| 85 years and over | 6 | 7 | 13 |
| Sex: Female, Male(Participants) | Nivo + Rela FDC SC | Nivo + Rela FDC IV | Total |
|---|---|---|---|
| Female | 109 | 120 | 229 |
| Male | 177 | 172 | 349 |
| Ethnicity (NIH/OMB)(Participants) | Nivo + Rela FDC SC | Nivo + Rela FDC IV | Total |
|---|---|---|---|
| Hispanic or Latino | 58 | 65 | 123 |
| Not Hispanic or Latino | 193 | 209 | 402 |
| Unknown or Not Reported | 35 | 18 | 53 |
| Race/Ethnicity, Customized(Participants) | Nivo + Rela FDC SC | Nivo + Rela FDC IV | Total |
|---|---|---|---|
| White | 239 | 264 | 503 |
| Black or African-American | 4 | 3 | 7 |
| Asian | 1 | 0 | 1 |
| Multiple | 2 | 6 | 8 |
| Unknown | 40 | 19 | 59 |
Showing the first 100 of 149 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Mar 2023 to primary completion in Aug 2025, 28 months.
Results were first posted in Aug 2026, 1 year after primary completion.
Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 28 months is below that.
Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Relatlimab